These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 23023561)

  • 1. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
    Peacock SO; Fahrenholtz CD; Burnstein KL
    Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
    Magani F; Peacock SO; Rice MA; Martinez MJ; Greene AM; Magani PS; Lyles R; Weitz JR; Burnstein KL
    Mol Cancer Res; 2017 Nov; 15(11):1469-1480. PubMed ID: 28811363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer.
    Rao S; Lyons LS; Fahrenholtz CD; Wu F; Farooq A; Balkan W; Burnstein KL
    Oncogene; 2012 Feb; 31(6):716-27. PubMed ID: 21765461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
    Lyons LS; Rao S; Balkan W; Faysal J; Maiorino CA; Burnstein KL
    Mol Endocrinol; 2008 Mar; 22(3):597-608. PubMed ID: 18079321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
    Lyons LS; Burnstein KL
    Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
    Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
    Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
    Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
    Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
    Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
    Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
    Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
    Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
    Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
    Krause WC; Shafi AA; Nakka M; Weigel NL
    Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors.
    Sun F; Chen HG; Li W; Yang X; Wang X; Jiang R; Guo Z; Chen H; Huang J; Borowsky AD; Qiu Y
    J Biol Chem; 2014 Jan; 289(3):1529-39. PubMed ID: 24297183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.
    Wu F; Peacock SO; Rao S; Lemmon SK; Burnstein KL
    J Biol Chem; 2013 Feb; 288(8):5463-74. PubMed ID: 23281476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.
    Zhang X; Morrissey C; Sun S; Ketchandji M; Nelson PS; True LD; Vakar-Lopez F; Vessella RL; Plymate SR
    PLoS One; 2011; 6(11):e27970. PubMed ID: 22114732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
    Sun S; Sprenger CC; Vessella RL; Haugk K; Soriano K; Mostaghel EA; Page ST; Coleman IM; Nguyen HM; Sun H; Nelson PS; Plymate SR
    J Clin Invest; 2010 Aug; 120(8):2715-30. PubMed ID: 20644256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
    Dong Z; Liu Y; Lu S; Wang A; Lee K; Wang LH; Revelo M; Lu S
    Mol Endocrinol; 2006 Oct; 20(10):2315-25. PubMed ID: 16762975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
    Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
    PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.